InnoPharmax Inc. (TPEX:4172)
Taiwan · Delayed Price · Currency is TWD 18.35
+3.80 (26.12%)
Apr 20, 2026, 1:20 PM CST
InnoPharmax Revenue
In the year 2025, InnoPharmax had annual revenue of 68.99M TWD with 113.60% growth. InnoPharmax had revenue of 46.64M in the half year ending June 30, 2025, with 34.61% growth.
Revenue
68.99M
Revenue Growth
+113.60%
P/S Ratio
22.69
Revenue / Employee
2.09M
Employees
33
Market Cap
1.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68.99M | 36.69M | 113.60% |
| Dec 31, 2024 | 32.30M | -13.78M | -29.90% |
| Dec 31, 2023 | 46.07M | 16.94M | 58.15% |
| Dec 31, 2022 | 29.13M | -18.93M | -39.38% |
| Dec 31, 2021 | 48.06M | -88.82M | -64.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.34B |
| Prince Pharmaceutical | 1.06B |
| Excelsior Biopharma | 898.26M |
| Anxo Pharmaceutical | 883.22M |
| DV Biomed | 794.18M |
| Winston Medical Supply | 700.07M |
| GeneFerm Biotechnology | 677.10M |
| Johnson Chemical Pharmaceutical Works | 569.77M |